欧洲实验室SARS-CoV-2检测灵敏度及变异分型能力外部质量评估
欧洲疾控中心资助的外部质量评估纳入34国59家实验室,用12份灭活样本(含10份不同浓度变异株)评估SARS-CoV-2分子检测与分型能力。72.9%实验室正确识别SARS-CoV-2 RNA,浓度≥25.0 copies/μL时98.3%可检出;商业试剂显著优于自建方法,变异分型平均仅5/10正确,联合RT-PCR与高通量测序者分型成功率更高。
要点
- 浓度≥25.0 copies/μL时98.3%实验室可检出SARS-CoV-2。
- 商业检测试剂得分显著优于自建方法(P<0.0001)。
- 变异分型平均仅5/10正确,联合方法优于单一方法(P=0.0345)。
核心结论
- 专家实验室对SARS-CoV-2检测灵敏度高,但变异分型准确性有限,需持续开发检测方法并联合不同技术。
研究设计与样本
- 欧洲疾控中心资助的外部质量评估,纳入34个欧洲国家59家实验室,使用12份冻干灭活样本(含10份SARS-CoV-2变异株及混合呼吸道病毒)。
主要发现
- 72.9%参与实验室正确识别SARS-CoV-2 RNA。
- 浓度≥25.0 copies/μL样本中98.3%实验室可检出SARS-CoV-2。
- 商业检测试剂得分显著优于自建方法(P<0.0001,Kruskal-Wallis检验)。
- 分子检测与变异分型均与RNA浓度相关(P<0.0001,Kruskal-Wallis检验)。
- 10份变异样本平均仅5份被正确分型,联合RT-PCR突变检测与高通量测序者分型成功率显著更高(P=0.0345,Kruskal-Wallis检验)。
关键数值与推荐
- 样本SARS-CoV-2浓度范围2.5至290.0 copies/μL。
- 浓度≥25.0 copies/μL时98.3%实验室检出。
- 72.9%实验室正确识别SARS-CoV-2 RNA。
- 变异分型平均正确5/10份。
临床怎么用
- 临床实验室应优先选用商业检测试剂以保证灵敏度。
- 变异分型建议联合RT-PCR突变检测与高通量测序以提高准确性。
- 应持续参加外部质量评估并优化低浓度样本检测流程。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The molecular detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is key for clinical management and surveillance. Funded by the European Centre for Disease Prevention and Control, we conducted an external quality assessment (EQA) on the molecular detection and variant typing of SARS-CoV-2 that included 59 European laboratories in 34 countries. The EQA panel consisted of 12 lyophilized inactivated samples, 10 of which were SARS-CoV-2 variants (Alpha, Beta, Gamma, Delta, Epsilon, Eta, parental B.1 strain) ranging from 2.5 to 290.0 copies/μL or pooled respiratory viruses (adenovirus, enterovirus, influenza virus A, respiratory syncytial virus, or human coronaviruses 229E and OC43). Of all participants, 72.9% identified the presence of SARS-CoV-2 RNA correctly. In samples containing 25.0 or more genome copies/μL, SARS-CoV-2 was detected by 98.3% of the participating laboratories. Laboratories applying commercial tests scored significantly better (P < 0.0001, Kruskal-Wallis test) than those using in-house assays. Both the molecular detection and the typing of the SARS-CoV-2 variants were associated with the RNA concentrations (P < 0.0001, Kruskal-Wallis test). On average, only 5 out of the 10 samples containing different SARS-CoV-2 variants at different concentrations were correctly typed. The identification of SARS-CoV-2 variants was significantly more successful among EQA participants who combined real-time reverse transcription polymerase chain reaction (RT-PCR)-based assays for mutation detection and high-throughput genomic sequencing than among those who used a single methodological approach (P = 0.0345, Kruskal-Wallis test). Our data highlight the high sensitivity of SARS-CoV-2 detection in expert laboratories as well as the importance of continuous assay development and the benefits of combining different methodologies for accurate SARS-CoV-2 variant typing.
引用
- Mögling R, Fischer C, Stanoeva KR, et al. Sensitivity of Detection and Variant Typing of SARS-CoV-2 in European Laboratories. J Clin Microbiol. 2022. PMID: 36445090. doi:10.1128/jcm.01261-22
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。